Table 1.
Clinical Characteristics of Polysubstance Use in Inflammatory Bowel Disease
| Variable | Total (n=315) | Polysubstance Use (n=66) | No Polysubstance Use (n=249) | Odds Ratio | 95% Confidence Limits | P Value | |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Gender [female (%)] | 166 (52.7%) | 34 (51.5%) | 132 (53.0%) | 0.94 | 0.55 | 1.62 | 0.89 |
| IBD subtype (CD/UC) | 214 / 101 | 46 / 20 | 168 / 81 | 0.90 | 0.50 | 1.62 | 0.77 |
| Moderate or severe inflammation (%) (on endoscopic evaluation) | 118 (37.5%) | 27 (40.9%) | 91 (36.5%) | 1.2 | 0.69 | 2.09 | 0.57 |
| Extra-intestinal manifestations (%) | 108 (34.3%) | 31 (47.0%) | 77 (30.9%) | 1.97 | 1.14 | 3.44 | 0.019 |
| Anxiety or depression (%) | 131 (41.6%) | 24 (36.4%) | 107 (43.0%) | 0.76 | 0.43 | 1.33 | 0.40 |
| Antidepressant or anxiolytic use (%) | 112 (35.6%) | 35 (53.0%) | 77 (30.9%) | 2.51 | 1.45 | 4.39 | <0.001 |
| Steroid use (%) | 167 (53.0%) | 37 (56.1%) | 130 (52.2%) | 1.17 | 0.68 | 2.02 | 0.68 |
| Mesalamine use (%) | 71 (22.5%) | 13 (19.7%) | 58 (23.3%) | 0.81 | 0.41 | 1.59 | 0.62 |
| Immunomodulatory use (%) | 75 (23.8%) | 13 (19.7%) | 62 (24.9%) | 0.74 | 0.38 | 1.45 | 0.42 |
| Biologic use (%) | 150 (47.6%) | 31 (47.0%) | 119 (47.8%) | 0.97 | 0.56 | 1.67 | 1.00 |
| Fatigue (%) | 270 (85.7%) | 55 (83.3%) | 215 (86.3%) | 0.79 | 0.38 | 1.66 | 0.55 |
| Abdominal pain (%) | 206 (65.4%) | 46 (69.7%) | 160 (64.3%) | 1.28 | 0.71 | 2.30 | 0.47 |
| Diarrhea (%) | 117 (37.1%) | 29 (43.9%) | 88 (35.3%) | 1.43 | 0.83 | 2.49 | 0.20 |
| Fecal urgency (%) | 218 (69.2%) | 52 (78.8%) | 166 (66.7%) | 1.85 | 0.97 | 3.54 | 0.072 |
| Rectal bleeding (%) | 125 (39.7%) | 27 (40.9%) | 98 (39.4%) | 1.07 | 0.61 | 1.85 | 0.89 |
| Healthcare resource utilization (%) | 220 (69.8%) | 50 (75.8%) | 170 (68.3%) | 1.45 | 0.78 | 2.71 | 0.29 |
Note: CD = Crohn’s disease; UC = ulcerative colitis.